Mersana Therapeutics Stock Forecast, Price & News

Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions

Is Mersana Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Mersana Therapeutics stock.
View analyst ratings for Mersana Therapeutics or view top-rated stocks.

How has Mersana Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Mersana Therapeutics' stock was trading at $6.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MRSN stock has increased by 7.6% and is now trading at $6.95.
View which stocks have been most impacted by COVID-19.

When is Mersana Therapeutics' next earnings date?

Mersana Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, February 25th 2022.
View our earnings forecast for Mersana Therapeutics.

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) released its earnings results on Tuesday, November, 9th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.05. Mersana Therapeutics had a negative net margin of 348,653.50% and a negative trailing twelve-month return on equity of 77.17%. During the same quarter in the previous year, the company earned ($0.33) EPS.
View Mersana Therapeutics' earnings history.

What price target have analysts set for MRSN?

5 equities research analysts have issued 1-year price objectives for Mersana Therapeutics' shares. Their forecasts range from $18.00 to $33.00. On average, they expect Mersana Therapeutics' stock price to reach $26.80 in the next twelve months. This suggests a possible upside of 285.6% from the stock's current price.
View analysts' price targets for Mersana Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Mersana Therapeutics' key executives?

Mersana Therapeutics' management team includes the following people:

• Anna Protopapas, President, Chief Executive Officer & Director (LinkedIn Profile)
• Brian DeSchuytner, Chief Financial Officer & Senior Vice President
• Timothy B. Lowinger, Chief Science & Technology Officer (LinkedIn Profile)
• Donna M. Jarlenski, Vice President-Clinical Operations
• Arvin Yang, Chief Medical Officer & Senior Vice President

What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO?

3 employees have rated Mersana Therapeutics CEO Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among Mersana Therapeutics' employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Mersana Therapeutics' key competitors?

Some companies that are related to Mersana Therapeutics include Taro Pharmaceutical Industries (TARO), Agios Pharmaceuticals (AGIO), Dynavax Technologies (DVAX), Turning Point Therapeutics (TPTX), Trillium Therapeutics (TRIL), Avid Bioservices (CDMO), Global Blood Therapeutics (GBT), Erasca (ERAS), Enanta Pharmaceuticals (ENTA), Ironwood Pharmaceuticals (IRWD), Morphic (MORF), Atai Life Sciences (ATAI), Myovant Sciences (MYOV), Travere Therapeutics (TVTX) and IVERIC bio (ISEE).
View all of MRSN's competitors.

What other stocks do shareholders of Mersana Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Marvell Technology (MRVL), Inovio Pharmaceuticals (INO), DocuSign (DOCU), Immunomedics (IMMU) and Marinus Pharmaceuticals (MRNS).

When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an initial public offering on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Who are Mersana Therapeutics' major shareholders?

Mersana Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.27%), Wellington Management Group LLP (8.37%), Sarissa Capital Management LP (5.99%), Bellevue Group AG (5.94%), Rock Springs Capital Management LP (4.21%) and Candriam Luxembourg S.C.A. (2.82%). Company insiders that own Mersana Therapeutics stock include Andrew A F Hack, Anna Protopapas, Ashish Mandelia, Eva M Jack, Lawrence M Alleva, Lawrence M Alleva, Scott D Sandell and Timothy B Lowinger.
View institutional ownership trends for Mersana Therapeutics.

Which institutional investors are selling Mersana Therapeutics stock?

MRSN stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Millennium Management LLC, Two Sigma Investments LP, Assenagon Asset Management S.A., Deutsche Bank AG, Caption Management LLC, Citigroup Inc., and Allianz Asset Management GmbH. Company insiders that have sold Mersana Therapeutics company stock in the last year include Anna Protopapas, Ashish Mandelia, and Timothy B Lowinger.
View insider buying and selling activity for Mersana Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Mersana Therapeutics stock?

MRSN stock was acquired by a variety of institutional investors in the last quarter, including Bellevue Group AG, Goldman Sachs Group Inc., Morgan Stanley, Marshall Wace LLP, Sarissa Capital Management LP, First Manhattan Co., Rock Springs Capital Management LP, and Voloridge Investment Management LLC. Company insiders that have bought Mersana Therapeutics stock in the last two years include Andrew A F Hack, and Lawrence M Alleva.
View insider buying and selling activity for Mersana Therapeutics or or view top insider-buying stocks.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mersana Therapeutics' stock price today?

One share of MRSN stock can currently be purchased for approximately $6.95.

How much money does Mersana Therapeutics make?

Mersana Therapeutics has a market capitalization of $499.79 million and generates $830 thousand in revenue each year. The company earns $-88.04 million in net income (profit) each year or ($2.14) on an earnings per share basis.

How many employees does Mersana Therapeutics have?

Mersana Therapeutics employs 110 workers across the globe.

What is Mersana Therapeutics' official website?

The official website for Mersana Therapeutics is www.mersana.com.

Where are Mersana Therapeutics' headquarters?

Mersana Therapeutics is headquartered at 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139.

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at (617) 498-0020 or via email at [email protected].